CHESHIRE, Conn., Mar 22, 2007 /PRNewswire via COMTEX News Network/ -- CHESHIRE, Conn., March 22 /PRNewswire-FirstCall/ -- Alexion Pharmaceuticals (Nasdaq: ALXN), today announced that the Company will conduct a conference call and audio webcast on Monday, March 26, 2007, at 9:00a.m. Eastern Time (ET), to discuss the U.S. commercial launch of Soliris(TM). Soliris was approved, on March 16, 2007, by the U.S. Food and Drug Administration for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis.
To participate in this conference call, dial (913) 312-1298, confirmation code 4755709, shortly before 9:00a.m. ET. A replay of the call will be available from 12:00p.m. ET through a limited time thereafter. The replay number is (719) 457-0820, confirmation code 4755709. The audio webcast can be accessed at: http://www.alexionpharm.com.
SOURCE Alexion Pharmaceuticals, Inc.
Leonard Bell, M.D., Chief Executive Officer of Alexion Pharmaceuticals, Inc., +1-203-272-2596; or Media, David Patti of Makovsky & Company, +1-212-508-9623, or Investors, Rhonda Chiger of Rx Communications, +1-917-322-2569, both for Alexion Pharmaceuticals
Copyright (C) 2007 PR Newswire. All rights reserved
News Provided by COMTEX